General MedicationsINTRAMUSCULARStandard

ZIPRASIDONE MESYLATE

Standard Dose

EQ 20MG BASE/VIAL

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview ZIPRASIDONE MESYLATE is listed in Drugs@FDA under application 217595 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ZIPRASIDONE MESYLATE Form and strength POWDER;INTRAMUSCULAR - EQ 20MG BASE/VIAL Sponsor STERISCIENCE Submission history Latest submission status date: 2025-09-03 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZIPRASIDONE MESYLATE is listed in Drugs@FDA under application 217595 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ZIPRASIDONE MESYLATE Form and strength POWDER;INTRAMUSCULAR - EQ 20MG BASE/VIAL Sponsor STERISCIENCE Submission history Latest submission status date: 2025-09-03 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.